345 related articles for article (PubMed ID: 26731476)
1. Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Kim TD; Jin F; Shin S; Oh S; Lightfoot SA; Grande JP; Johnson AJ; van Deursen JM; Wren JD; Janknecht R
J Clin Invest; 2016 Feb; 126(2):706-20. PubMed ID: 26731476
[TBL] [Abstract][Full Text] [Related]
2. ETS transcription factor ERG cooperates with histone demethylase KDM4A.
Kim TD; Shin S; Janknecht R
Oncol Rep; 2016 Jun; 35(6):3679-88. PubMed ID: 27109047
[TBL] [Abstract][Full Text] [Related]
3. SET7/9-mediated methylation affects oncogenic functions of histone demethylase JMJD2A.
Gu R; Kim TD; Song H; Sui Y; Shin S; Oh S; Janknecht R
JCI Insight; 2023 Oct; 8(20):. PubMed ID: 37870957
[TBL] [Abstract][Full Text] [Related]
4. Cooperation between ETS transcription factor ETV1 and histone demethylase JMJD1A in colorectal cancer.
Oh S; Song H; Freeman WM; Shin S; Janknecht R
Int J Oncol; 2020 Dec; 57(6):1319-1332. PubMed ID: 33174020
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of PSMD10 caused by the JMJD2A histone demethylase.
Kim TD; Oh S; Lightfoot SA; Shin S; Wren JD; Janknecht R
Int J Clin Exp Med; 2016; 9(6):10123-10134. PubMed ID: 28883898
[TBL] [Abstract][Full Text] [Related]
6. ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer.
Liu CY; Yu T; Huang Y; Cui L; Hong W
J Biol Chem; 2017 Jun; 292(22):9420-9430. PubMed ID: 28408625
[TBL] [Abstract][Full Text] [Related]
7. Cooperation between ETS variant 2 and Jumonji domain‑containing 2 histone demethylases.
Li X; Moon G; Shin S; Zhang B; Janknecht R
Mol Med Rep; 2018 Apr; 17(4):5518-5527. PubMed ID: 29393482
[TBL] [Abstract][Full Text] [Related]
8. MiR-10a functions as a tumor suppressor in prostate cancer via targeting KDM4A.
Mu H; Xiang L; Li S; Rao D; Wang S; Yu K
J Cell Biochem; 2019 Apr; 120(4):4987-4997. PubMed ID: 30302800
[TBL] [Abstract][Full Text] [Related]
9. Lgr4 promotes prostate tumorigenesis through the Jmjd2a/AR signaling pathway.
Zhang J; Li Q; Zhang S; Xu Q; Wang T
Exp Cell Res; 2016 Nov; 349(1):77-84. PubMed ID: 27743893
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic features of the JMJD2A histone demethylase in breast cancer.
Berry WL; Shin S; Lightfoot SA; Janknecht R
Int J Oncol; 2012 Nov; 41(5):1701-6. PubMed ID: 22948256
[TBL] [Abstract][Full Text] [Related]
11. Histone demethylase KDM3A is required for enhancer activation of hippo target genes in colorectal cancer.
Wang HY; Long QY; Tang SB; Xiao Q; Gao C; Zhao QY; Li QL; Ye M; Zhang L; Li LY; Wu M
Nucleic Acids Res; 2019 Mar; 47(5):2349-2364. PubMed ID: 30649550
[TBL] [Abstract][Full Text] [Related]
12. Targeting USP1-dependent KDM4A protein stability as a potential prostate cancer therapy.
Cui SZ; Lei ZY; Guan TP; Fan LL; Li YQ; Geng XY; Fu DX; Jiang HW; Xu SH
Cancer Sci; 2020 May; 111(5):1567-1581. PubMed ID: 32133742
[TBL] [Abstract][Full Text] [Related]
13. The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice.
Zhang QJ; Chen HZ; Wang L; Liu DP; Hill JA; Liu ZP
J Clin Invest; 2011 Jun; 121(6):2447-56. PubMed ID: 21555854
[TBL] [Abstract][Full Text] [Related]
14. JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5.
Mallette FA; Richard S
Cell Rep; 2012 Nov; 2(5):1233-43. PubMed ID: 23168260
[TBL] [Abstract][Full Text] [Related]
15. Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
Lunardi A; Varmeh S; Chen M; Taulli R; Guarnerio J; Ala U; Seitzer N; Ishikawa T; Carver BS; Hobbs RM; Quarantotti V; Ng C; Berger AH; Nardella C; Poliseno L; Montironi R; Castillo-Martin M; Cordon-Cardo C; Signoretti S; Pandolfi PP
Cancer Discov; 2015 May; 5(5):550-63. PubMed ID: 25653093
[TBL] [Abstract][Full Text] [Related]
16. ETS rearrangements and prostate cancer initiation.
Carver BS; Tran J; Chen Z; Carracedo-Perez A; Alimonti A; Nardella C; Gopalan A; Scardino PT; Cordon-Cardo C; Gerald W; Pandolfi PP
Nature; 2009 Feb; 457(7231):E1; discussion E2-3. PubMed ID: 19212347
[TBL] [Abstract][Full Text] [Related]
17. Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D.
Shin S; Janknecht R
Biochem Biophys Res Commun; 2007 Aug; 359(3):742-6. PubMed ID: 17555712
[TBL] [Abstract][Full Text] [Related]
18. Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.
Shin S; Kim TD; Jin F; van Deursen JM; Dehm SM; Tindall DJ; Grande JP; Munz JM; Vasmatzis G; Janknecht R
Cancer Res; 2009 Oct; 69(20):8102-10. PubMed ID: 19789348
[TBL] [Abstract][Full Text] [Related]
19. COP1 is a tumour suppressor that causes degradation of ETS transcription factors.
Vitari AC; Leong KG; Newton K; Yee C; O'Rourke K; Liu J; Phu L; Vij R; Ferrando R; Couto SS; Mohan S; Pandita A; Hongo JA; Arnott D; Wertz IE; Gao WQ; French DM; Dixit VM
Nature; 2011 May; 474(7351):403-6. PubMed ID: 21572435
[TBL] [Abstract][Full Text] [Related]
20. HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372.
An J; Xu J; Li J; Jia S; Li X; Lu Y; Yang Y; Lin Z; Xin X; Wu M; Zheng Q; Pu H; Gui X; Li T; Lu D
Oncotarget; 2017 Jul; 8(30):49093-49109. PubMed ID: 28467776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
